Our product development strategy is focused on creating products with a predicted high rate of return on investment and a low cost of development.
We focus exclusively on topically applied pharmaceutical drugs and medical devices. We only incorporate existing well-characterised chemical entities into our products. This strategy gives us a lower development risk profile compared with developing new chemical entities. As a result, the overall risk of the investment is reduced as our strategy increases the likelihood of regulatory approval and lowers the cost of development.
In addition to our developing portfolio of sexual healthcare and pain relief management products we are looking at incorporating our proprietary delivery system DermaSys® into other products that may fall outside of these current areas provided that we believe they offer a compelling commercial opportunity.
In addition to the six products already in our development pipeline for sexual healthcare and pain relief management: CSD500, PET500, MED2002, TPR100, TPR100-Rx and RAD100 we are exploring several new peroduct opportunities.
To view our product pipeline, follow this link.